AssetMark Inc
AUPH icon

AssetMark Inc’s Aurinia Pharmaceuticals AUPH Stock Holding History

AssetMark Inc’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.46K Buy
204
+81
+66% +$1.29K ﹤0.01% 2812
2026
Q1 		$1.82K Hold
123
– – ﹤0.01% 2883
2025
Q4 		$1.96K Hold
123
– – ﹤0.01% 2780
2025
Q3 		$1.36K Buy
+123
New +$1.34K ﹤0.01% 2721

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AssetMark Inc's AUPH Position: Q2 2026 in Review

AssetMark Inc increased its Aurinia Pharmaceuticals (AUPH) stake by 66% in Q2 2026, buying an estimated $1.29K and bringing the position to 204 shares worth $3.46K. The position accounts for ﹤0.01% of the portfolio, ranked #2812.

AssetMark Inc first reported a position in AUPH in Q3 2025 and has held it in 4 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • AssetMark Inc held 204 shares of Aurinia Pharmaceuticals worth $3.46K as of Q2 2026.
  • AssetMark Inc bought 81 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $1.29K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2812 holding.
  • AssetMark Inc first reported a position in Aurinia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.